These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38752627)

  • 1. The Impact of Gastroesophageal Reflux Disease and Proton Pump Inhibitor Use on the Risk of Repeat Catheter Ablation for Atrial Fibrillation.
    Cai JX; Algara M; Lo WK; Kapur S; Chan WW
    Clin Transl Gastroenterol; 2024 Jun; 15(6):e00717. PubMed ID: 38752627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis.
    Chen CH; Lin CL; Kao CH
    Osteoporos Int; 2016 Jun; 27(6):2117-26. PubMed ID: 26860609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atrial fibrillation in patients with gastroesophageal reflux disease: a comprehensive review.
    Roman C; Bruley des Varannes S; Muresan L; Picos A; Dumitrascu DL
    World J Gastroenterol; 2014 Jul; 20(28):9592-9. PubMed ID: 25071357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Vonoprazan for Gastroesophageal Reflux Symptoms in Patients with Proton Pump Inhibitor-resistant Non-erosive Reflux Disease.
    Niikura R; Yamada A; Hirata Y; Hayakawa Y; Takahashi A; Shinozaki T; Takeuchi Y; Fujishiro M; Koike K
    Intern Med; 2018 Sep; 57(17):2443-2450. PubMed ID: 29607951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastroesophageal reflux disease, proton-pump inhibitor use and Barrett's esophagus in esophageal adenocarcinoma: Trends revisited.
    Lada MJ; Nieman DR; Han M; Timratana P; Alsalahi O; Peyre CG; Jones CE; Watson TJ; Peters JH
    Surgery; 2013 Oct; 154(4):856-64; discussion 864-6. PubMed ID: 24074425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atrial fibrillation ablation in patients with gastroesophageal reflux disease or irritable bowel syndrome-the heart to gut connection!
    Reddy YM; Singh D; Nagarajan D; Pillarisetti J; Biria M; Boolani H; Emert M; Chikkam V; Ryschon K; Vacek J; Bommana S; Atkins D; Verma A; Olyaee M; Dawn B; Lakkireddy D
    J Interv Card Electrophysiol; 2013 Sep; 37(3):259-65. PubMed ID: 23736874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New treatment method for refractory gastroesophageal reflux disease (GERD): C-BLART (clip band ligation anti-reflux therapy)-a short-term study.
    Liu S; Chai N; Zhai Y; Zou J; Feng X; Li Z; Li L; Zhang X; Wang X; Wang S; Linghu EQ
    Surg Endosc; 2020 Oct; 34(10):4516-4524. PubMed ID: 31728750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized controlled trial of transoral incisionless fundoplication vs. proton pump inhibitors for treatment of gastroesophageal reflux disease.
    Witteman BP; Conchillo JM; Rinsma NF; Betzel B; Peeters A; Koek GH; Stassen LP; Bouvy ND
    Am J Gastroenterol; 2015 Apr; 110(4):531-42. PubMed ID: 25823768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More severe upper gastrointestinal symptoms associated with non-erosive reflux disease than with erosive gastroesophageal reflux disease during maintenance proton pump inhibitor therapy.
    Kusano M; Hosaka H; Kawamura O; Kawada A; Kuribayashi S; Shimoyama Y; Yasuoka H; Mizuide M; Tomizawa T; Sagawa T; Sato K; Yamada M
    J Gastroenterol; 2015 Mar; 50(3):298-304. PubMed ID: 24919745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atrial fibrillation and gastroesophageal reflux disease: the cardiogastric interaction.
    Linz D; Hohl M; Vollmar J; Ukena C; Mahfoud F; Böhm M
    Europace; 2017 Jan; 19(1):16-20. PubMed ID: 27247004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of on-demand vs continuous prescription of proton pump inhibitors on symptom burden and quality of life: results of a real-world randomized controlled trial in primary care patients with gastroesophageal reflux disease.
    Andreasson A; Agréus L; Mastellos N; Bliźniuk G; Waśko-Czopnik D; Angelaki A; Theodosaki E; Lionis C; Hek K; Verheij R; Wright E; Durbaba S; Muris J; Bródka P; Saganowski S; Ethiér JF; Curcin V; Delaney B
    Ann Med; 2024 Dec; 56(1):2354683. PubMed ID: 38753973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS?
    Azzam RS
    Arq Gastroenterol; 2018 Nov; 55Suppl 1(Suppl 1):85-91. PubMed ID: 30304291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Univariate and multivariate analyses of preoperative factors influencing symptomatic outcomes of transoral fundoplication.
    Bell RC; Fox MA; Barnes WE; Mavrelis PG; Sewell RW; Carter BJ; Ihde GM; Trad KS; Dargis D; Hoddinott KM; Freeman KD; Gunsberger T; Hausmann MG; Gill BD; Wilson E
    Surg Endosc; 2014 Oct; 28(10):2949-58. PubMed ID: 24879134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-year follow-up after catheter ablation of persistent atrial fibrillation using the stepwise approach and prognostic factors for success.
    Schreiber D; Rostock T; Fröhlich M; Sultan A; Servatius H; Hoffmann BA; Lüker J; Berner I; Schäffer B; Wegscheider K; Lezius S; Willems S; Steven D
    Circ Arrhythm Electrophysiol; 2015 Apr; 8(2):308-17. PubMed ID: 25744570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent dysphagia is a rare problem after laparoscopic Nissen fundoplication.
    Nikolic M; Schwameis K; Semmler G; Asari R; Semmler L; Steindl A; Mosleh BO; Schoppmann SF
    Surg Endosc; 2019 Apr; 33(4):1196-1205. PubMed ID: 30171395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term benefit of transoral incisionless fundoplication using the esophyx device for the management of gastroesophageal reflux disease responsive to medical therapy.
    Stefanidis G; Viazis N; Kotsikoros N; Tsoukalas N; Lala E; Theocharis L; Fassaris A; Manolakopoulos S
    Dis Esophagus; 2017 Feb; 30(3):1-8. PubMed ID: 27868281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of endoscopic fundoplication and proton pump inhibitors on baseline impedance and heartburn severity in GERD patients.
    Rinsma NF; Farré R; Bouvy ND; Masclee AA; Conchillo JM
    Neurogastroenterol Motil; 2015 Feb; 27(2):220-8. PubMed ID: 25348594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastroesophageal reflux disease-related symptom recurrence in patients discontinuing proton pump inhibitors for Bravo
    Schey R; Alla SP; Midani D; Parkman HP
    Rev Gastroenterol Mex; 2017; 82(4):277-286. PubMed ID: 28385467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reflux esophagitis in the pathogenesis of paroxysmal atrial fibrillation: results of a pilot study.
    Weigl M; Gschwantler M; Gatterer E; Finsterer J; Stöllberger C
    South Med J; 2003 Nov; 96(11):1128-32. PubMed ID: 14632362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot study on anti-reflux mucoplasty: Advancing endoscopic anti-reflux therapy for gastroesophageal reflux disease.
    Inoue H; Yamamoto K; Shimamura Y; Azuma D; Ushikubo K; Okada H; Kimoto Y; Nishikawa Y; Tanaka I; Tanabe M; Onimaru M; Navarro MJ
    Dig Endosc; 2024 Jun; 36(6):690-698. PubMed ID: 37899073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.